Navigation Links
Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
Date:9/14/2011

experimental vaccines for safety and the ability to stimulate immune responses, to testing vaccine efficacy. Support for the HVTN comes from the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The Network's HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents. Internationally renowned HIV vaccine and prevention researchers lead the units.

About Inovio Pharmaceuticals, Inc. Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon® vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
2. Inovio Pharmaceuticals to Present at Investor Conferences
3. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
4. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
5. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
6. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
7. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
8. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
9. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
10. Inovio Pharmaceuticals to Present at Investor Conferences
11. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Switzerland, September 15, 2010 ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... 14 ThermoGenesis Corp. (Nasdaq: KOOLD ), a ... store adult stem cells, said today that revenues for the ... of $4.0 million for the same quarter a year ago. ... million. The Company recorded disposable revenues of $4.8 ...
Cached Medicine Technology:ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 2ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 3ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 4ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 5ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 6ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk 7ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 2ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 3ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 4ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 5ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 6ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000 7
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... By Amy Norton ... -- Yoga has long been believed to improve overall health, ... may also help the heart, a new review finds. ... exercise such as brisk walking, said lead researcher Paula Chu, ... Boston. The review, of 37 clinical trials, found that ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... , The inactivity or "silence" of certain genes ... leukemia as well as in response to treatment, according to ... specialists from the University Hospital of Navarra and the Center ... as well as the Reina Sofa Hospital in Cordoba, Andalusia. ...
... Company, the nation,s leading builder of healthcare facilities, has ... with the $42 million Phase Two expansion to the ... in March 2009 with completion scheduled for March 2011. ... emergency rooms, ICU, CCU, three operating rooms and 26 ...
... Link as SCHIP Legislation Signed Into LawWASHINGTON, Feb. ... voice for more than 36,000 frontline providers of ... commended President Barack Obama for singling out the ... signed an historic expansion of the State Children,s ...
... missed key DNA variant, researchers say , , FRIDAY, Feb. ... DNA called copy number variants may play a role ... findings support a sharp change of direction in genetics ... decades, researchers have identified dozens of genes and single ...
... ,History Shows Avalon Is No Champion of Corporate Governance,TUCSON, ... PRSC ) today commented on the recent ... Inc. (Pink Sheets: CITY) together with other related persons, ... sole director of Avalon, intends to initiate a consent ...
... Feb. 6 ev3 Inc. (Nasdaq: EVVV ) ... and its financial guidance for 2009 on Tuesday, Febuary 24, ... conference call and webcast the same day at 7:30 a.m. ... review its fourth quarter and full-year operating results and future ...
Cached Medicine News:Health News:New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Doctors of Optometry Cheer Obama's Call to Action on Children's Vision 2Health News:Doctors of Optometry Cheer Obama's Call to Action on Children's Vision 3Health News:Genome Study Points to New Culprit for Schizophrenia 2Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 2Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 3Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 4Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 5Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 6Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 7Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
For general purposes...
... BcMag Streptavidin magnetic beads are ... of biotinylated molecules such as ... from cell lysates or hybridization ... highly dispersed, it can also ...
Medicine Products: